Sanofi - Company Profile
Powered by 
All the data and insights you need on Sanofi in one report.
$295
- Save hours of research time and resources with
our up-to-date Sanofi Strategy Report
- Understand Sanofi position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreSanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.
Headquarters
France
Address
46 Avenue De La Grande Armee, Paris, Ile-de-France, 75017
Website
www.sanofi.com
Telephone
33 1 53774000
No of Employees
91,573
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SAN (EPA)
Revenue (2022)
$47.7B
15.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
34.5%
(2022 vs 2021)
Market Cap*
$119.2B
Net Profit Margin (2022)
XYZ
16.1%
(2022 vs 2021)
* As of and is in US$
Sanofi premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Dupixent |
| Specialty Care: | Aubagio |
| Atopic Dermatitis | Lemtrada |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company formed a strategic collaboration with BioMap to co-develop new protein therapies. |
| 2023 | Plans/Strategy | In October, the company announced its plans to acquire Mirati Therapeutics. |
| 2023 | Contracts/Agreements | In October, the company and Teva Pharmaceuticals entered into a collaboration to co-develop and co-commercialize asset TEV ‘574. |
Competitor Comparison
| Key Parameters | Sanofi | Pfizer Inc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | Switzerland | United States of America |
| City | Paris | New York | New Brunswick | Basel | Kenilworth |
| State/Province | Ile-de-France | New York | New Jersey | - | New Jersey |
| No. of Employees | 91,573 | 83,000 | 152,700 | 103,613 | 69,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Hudson | Director; Chief Executive Officer | Executive Board | 2019 | 55 |
| Jean-Baptiste Chasseloup de Chatillon | Executive Vice President; Chief Financial Officer | Senior Management | 2018 | 58 |
| Natalie Bickford | Executive Vice President; Chief People Officer | Senior Management | 2020 | 53 |
| Emmanuel Frenehard | Chief Digital Officer | Senior Management | 2023 | - |
| Frederic Oudea | Chairman | Non Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward